|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1991-9-26
|
|
pubmed:abstractText |
beta-HET (beta-Hydroxyethyltheophylline), the major metabolite of the antibronchospastic, antiasthmatic drug doxofylline was studied in several in vitro and in vivo trials to characterize its pharmaco-toxicological profile. When compared to the parent compound, beta-HET was found to be significantly less active. It was also discovered to be a very weak inhibitor of phosphodiesterase activity. Its affinity for A1- and A2-adenosine receptors was even lower than that of doxofylline, which was quite low. The oral toxicity of beta-HET was about three times lower than that of doxofylline. The pharmacological activity of doxofylline is due to the drug in its original form and not to its major metabolite.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases,
http://linkedlifedata.com/resource/pubmed/chemical/Acetylcholine,
http://linkedlifedata.com/resource/pubmed/chemical/Antitussive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Epinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Theophylline,
http://linkedlifedata.com/resource/pubmed/chemical/doxofylline,
http://linkedlifedata.com/resource/pubmed/chemical/etofylline
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0379-0355
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
289-99
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1652045-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:1652045-Acetylcholine,
pubmed-meshheading:1652045-Animals,
pubmed-meshheading:1652045-Antitussive Agents,
pubmed-meshheading:1652045-Blood Pressure,
pubmed-meshheading:1652045-Bronchial Spasm,
pubmed-meshheading:1652045-Bronchodilator Agents,
pubmed-meshheading:1652045-Electrocardiography,
pubmed-meshheading:1652045-Epinephrine,
pubmed-meshheading:1652045-Female,
pubmed-meshheading:1652045-Guinea Pigs,
pubmed-meshheading:1652045-Humans,
pubmed-meshheading:1652045-Ileum,
pubmed-meshheading:1652045-Lethal Dose 50,
pubmed-meshheading:1652045-Male,
pubmed-meshheading:1652045-Movement,
pubmed-meshheading:1652045-Muscle, Smooth,
pubmed-meshheading:1652045-Muscle Contraction,
pubmed-meshheading:1652045-Rabbits,
pubmed-meshheading:1652045-Rats,
pubmed-meshheading:1652045-Receptors, Purinergic,
pubmed-meshheading:1652045-Serotonin,
pubmed-meshheading:1652045-Stimulation, Chemical,
pubmed-meshheading:1652045-Theophylline,
pubmed-meshheading:1652045-Trachea,
pubmed-meshheading:1652045-Vagus Nerve
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Pharmacological studies in animals of beta-hydroxyethyltheophylline, the major metabolite of doxofylline in humans.
|
|
pubmed:affiliation |
Istituto Biologico Chemioterapico ABC S.p.A., Research Laboratories, Torino, Italy.
|
|
pubmed:publicationType |
Journal Article
|
